title: Variable toxicological response to the loss of OXPHOS through 1-methyl-4-phenylpyridinium-induced mitochondrial damage and anoxia in diverse neural immortal cell lines.
abstract: Immortal cell lines are used to investigate various aspects of neurodegeneration. These cells display high glycolytic turnover rate and produce an abundant amounts of lactate. Our previous studies indicate that these cells survive the loss of mitochondrial oxidative phosphorylation (OXPHOS) with ample glucose supply. In the current study, we investigate if cell type (w/variation in basal metabolic rate (MR)), can alter glucose utilization patterns which in turn may affect LC(50) for the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)) in various cell lines. The data obtained indicate that cell lines MRs examined were generally consistent with the average of species adult body weight where mouse N-2A > rat-PC-12 > human SH-SY5Y. A higher MR was associated with accelerated utilization of glucose and earlier cell death with MPP(+): LC(50) mouse = 294 µM, rat = 695 µM, and human = 5.25 mM at 24 h. Cell death appears to be a function of the velocity by which glucose disappears, leading to the failure of glycolysis and subsequent halt of energy production. Similar effects were also observed at higher plating densities where the demand for glucose is amplified. A time-lapse study of MPP(+) toxicity (0-36 h) in N-2A cells indicates that an anaerobic shift occurs as early as 2 h (evidenced by a rise in lactate), followed by a descent in glucose concentrations at 4 h and exhaustion of glucose supplies at 22 h which was associated with the first detectable sign of cell death. It was also noted that MPP(+) toxicity was not associated with the generation of reactive oxygen species (O (2) (-) , H(2)0(2), and NO(2)) and was not attenuated by adding catalase or superoxide dismutase to the media. On the other hand, MPP(+) toxicity was reversed by providing additional supply of glucose, pyruvate ± mitochondrial monocarboxylate transporter blocker (α-cyano-4-HCA), or pyruvate ± pyruvate dehydrogenase inhibitor (octanoyl-CoA), suggesting that the exclusive anaerobic survival compensates for the loss of OXPHOS by MPP(+). To examine if neuroblastoma were capable of surviving the deprivation of O(2) for 24 h, a range of hypoxia to anoxia was established with various concentrations of dithionite. The data suggest that cell lines examined continue to thrive when incubated with high-glucose media (25 mM). In summary, vulnerability of immortal neuroblastoma cell lines to MPP(+) toxicity is dependent upon glucose concentrations within the media and cell MR, which indirectly dominates the velocity of glucose use and its end point disappearance, leading to cell death by ergogenic failure.
authors.affiliation: College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Dyson Building-Room 104, Tallahassee, FL 32307, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mazzio
authors.forename: Youssef I
authors.initials: YI
authors.lastname: Soliman
authors.forename: Karam F A
authors.initials: KF
authors.lastname: Soliman
mesh_terms: D015655:1-Methyl-4-phenylpyridinium / Q000633:toxicity*; D000818:Animals; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D006540:Herbicides / Q000633:toxicity*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D010085:Oxidative Phosphorylation / Q000187:drug effects*; D051381:Rats
chemical_list: D006540:Herbicides; D015655:1-Methyl-4-phenylpyridinium
references.citation: Planta Med. 2003 Jan;69(1):65-6
references.pmid: 12567282
references.citation: Brain Res. 1998 Oct 26;809(1):58-67
references.pmid: 9795136
references.citation: J Neurosci Res. 1994 Nov 1;39(4):405-11
references.pmid: 7533844
references.citation: Brain Res. 1985 Dec 9;358(1-2):137-43
references.pmid: 3878182
references.citation: Eur J Pharmacol. 1997 Jul 2;330(1):27-34
references.pmid: 9228411
references.citation: J Pharmacol Exp Ther. 2004 Jun;309(3):1067-78
references.pmid: 14985416
references.citation: J Neurochem. 1992 Mar;58(3):1052-9
references.pmid: 1737983
references.citation: Mod Pathol. 1998 Apr;11(4):392-6
references.pmid: 9578091
references.citation: J Biol Chem. 1951 Nov;193(1):265-75
references.pmid: 14907713
references.citation: Neurosci Bull. 2007 Nov;23(6):329-35
references.pmid: 18064062
references.citation: J Food Sci. 2008 Sep;73(7):H174-8
references.pmid: 18803714
references.citation: J Bioenerg Biomembr. 2007 Jun;39(3):235-41
references.pmid: 17665292
references.citation: Biochem Pharmacol. 2002 Dec 15;64(12):1745-51
references.pmid: 12445863
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):476-84
references.pmid: 19147752
references.citation: Neurosci Lett. 2007 May 17;418(2):159-64
references.pmid: 17433543
references.citation: Toxicol In Vitro. 2001 Aug-Oct;15(4-5):579-84
references.pmid: 11566594
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1961-73
references.pmid: 18645006
references.citation: Brain Res. 2004 Apr 9;1004(1-2):29-44
references.pmid: 15033417
references.citation: Brain Res. 1984 May 28;301(1):187-91
references.pmid: 6610458
references.citation: Pharmacol Res. 2010 May;61(5):391-9
references.pmid: 20080185
references.citation: Sci STKE. 2007 Apr 10;2007(381):pe14
references.pmid: 17426345
references.citation: Neuroscience. 2007 Jul 13;147(3):746-56
references.pmid: 17583434
references.citation: Bull Cancer. 1998 Nov;85(11):935-50
references.pmid: 9951421
references.citation: Brain Res. 2008 Mar 4;1197:143-51
references.pmid: 18242592
references.citation: Neurotoxicology. 2009 Jan;30(1):127-35
references.pmid: 19056420
references.citation: Parkinsonism Relat Disord. 1999 Dec;5(4):221-9
references.pmid: 18591144
references.citation: Exp Neurol. 1988 Dec;102(3):307-13
references.pmid: 3264247
references.citation: Ann N Y Acad Sci. 1999;890:227-39
references.pmid: 10668429
references.citation: Orv Hetil. 2007 Jul 29;148(30):1415-20
references.pmid: 17631480
references.citation: Chemotherapy. 2007;53(4):233-56
references.pmid: 17595539
references.citation: J Neurosci Res. 2008 Jul;86(9):2083-90
references.pmid: 18381761
references.citation: Cell Mol Neurobiol. 2009 Dec;29(8):1169-80
references.pmid: 19466539
references.citation: Exp Neurol. 1995 Apr;132(2):279-83
references.pmid: 7789466
references.citation: Eur J Pharmacol. 2009 Feb 14;604(1-3):36-44
references.pmid: 19135049
references.citation: Novartis Found Symp. 2001;240:46-62; discussion 62-7, 152-3
references.pmid: 11727936
references.citation: Brain Res. 1988 Jun 21;453(1-2):227-34
references.pmid: 3261197
references.citation: J Neural Transm Suppl. 2007;(72):57-67
references.pmid: 17982879
references.citation: QJM. 2005 Mar;98(3):215-26
references.pmid: 15728403
references.citation: J Neurochem. 2008 Apr;105(1):225-38
references.pmid: 18021296
references.citation: J Neural Transm (Vienna). 2007 Sep;114(9):1155-9
references.pmid: 17431733
references.citation: Brain Res. 2003 Feb 7;962(1-2):48-60
references.pmid: 12543455
references.citation: Cancer Sci. 2006 Oct;97(10):1056-60
references.pmid: 16984378
references.citation: Cell Biol Int. 2009 Sep;33(9):957-63
references.pmid: 19524685
references.citation: Clin Exp Pharmacol Physiol. 2010 May;37(5-6):530-5
references.pmid: 20529091
references.citation: Eur J Pharmacol. 2007 Jul 30;568(1-3):142-8
references.pmid: 17512520
references.citation: Neurochem Int. 2000 May;36(6):489-97
references.pmid: 10762085
references.citation: Neurotoxicology. 2003 Jan;24(1):137-47
references.pmid: 12564389
references.citation: Eur J Neurosci. 2006 Feb;23(4):1077-81
references.pmid: 16519673
references.citation: Free Radic Biol Med. 2009 Apr 1;46(7):939-47
references.pmid: 19280713
references.citation: Neurol Res. 1992 Sep;14(4):289-93
references.pmid: 1360622
references.citation: Anal Biochem. 1997 Jan 15;244(2):384-92
references.pmid: 9025956
references.citation: Tumour Biol. 1988;9(5):241-8
references.pmid: 2973647
references.citation: Cancer Res. 2003 Jul 15;63(14):3847-54
references.pmid: 12873971